Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec in Ph+ Chronic Phase CML
NCT00030394Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2002
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myelogenous leukemia (CML), sponsored by National Cancer Institute. Primary endpoints: Response rate at 5 years, Disease-free survival at 5 years and 1 more. Started Sep 2002; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00030394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030394.